Knight Therapeutics announced that its Brazilian affiliate, United Medical Ltd., has received pricing approval for Minjuvi from the Drugs Market Regulation Chamber, CMED. As a result, Knight expects to launch Minjuvi in Brazil in the second quarter of 2024. The approval is based on the data from L-MIND, an open label, multicenter, single arm Phase 2 study, that evaluated Minjuvi in combination with lenalidomide for the treatment of adult patients with relapsed or refractory DLBCL. The study primary analysis results showed an objective response rate of 60%, including a complete response rate of 43% and a disease control rate of 75%.”We’re excited to continue to advance the approval of Minjuvi in Brazil, a new treatment option for a current unmet need. We look forward to launching Minjuvi in Brazil and obtaining approval in other key markets in Latin America,” said Samira Sakhia, Knight Therapeutics President and CEO.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on KHTRF:
